



*Interim Results for the  
six months ended  
31 August 2023*



## Contents

01 Group Performance Review	05 Condensed Statement of Financial Position	08 Accounting Policies
03 Condensed Statement of Comprehensive Income	06 Condensed Statement of Changes in Equity	09 Notes to the Interim Financial Statements
04 Headline Earnings	07 Condensed Statement of Cash Flows	10 Company information
04 Normalised EBITDA		

# Group Performance review

The Group had a strong start to the financial year on the back of increased activity in our existing business, complemented by the addition of Matlosana Medical Health Services (MMHS) during the last 12 months. Our organic growth initiatives embarked upon over the past 18 months have come to fruition, with good results noted to date and further opportunity for positive profit contribution going forward.

In line with our growth strategy, we acquired a 60% stake in Beira Private Hospital, in the town of Beira in Mozambique with effect from 15 March 2023. This transaction adds an additional 60 beds to the Group's base, as well as an outpatient clinic and aligns with our strategy of expanding our footprint in Mozambique, strengthening our care delivery network in that region.

Post the reporting period, Lenmed has also successfully concluded the acquisition of 100% of Mooimed Private Hospital (Mooimed) for an estimated net sum of R106 million with effect from 1 October 2023. Mooimed is an 83-bed private hospital based in Potchefstroom and expands the Group's footprint in the North-West province of South Africa. The acquisition price will be finalized subject to the audited cash and working capital balances at the acquisition date and will be settled over two tranches by no later than 1 December 2023.

Group Revenue improved by 28% to R2 382.9 million compared to R1 868.0 million in the same period last year. This improvement is attributable to an increase in Paid Patient Days (PPDs) of 22%, and an increase in the Rand per Patient Day (RPPD) of 4%. The growth in PPDs is predominantly due to a 26% increase in total admissions, while the length of stay reduced slightly along with the slight change in the case mix.

Other Income increased by 41% to R93.6 million from R66.6 million in the prior period largely as a result of our efforts to grow earnings from complementary services, most notable pathology, radiology and renal care. We continue to explore avenues to further increase the potential commercial benefit in this regard, with several pilot initiatives underway.

Reported Group earnings before interest, tax, depreciation and amortisation (EBITDA) improved by 15.4% to R380.0 million from R329.2 million in 2022.

EBITDA would have increased to R395.4 million (19% on the prior period) if not for the following items:

- once off transaction costs;
- once off business development costs relating to the Group's growth strategy across both periods; and
- the increased municipal costs such as rates, water and electricity and additional load shedding costs, which has collectively increased by 38% year-on-year.

Net interest expense increased 57% to R86.5 million (2022: R54.9 million) for the first half of the year. This increase is attributable to funding the acquisition of MMHS and a 38% increase in interest rates due to South African interest rate hikes.

As a result, Profit before tax grew by 8.4% to R208.2 million from R192.0 million.

In line with the Group's growth strategy, we have initiated internal growth initiatives with several high-acuity projects being planned and/or committed to during this period.

In addition to the investment in our own facilities, the Group funded the acquisition of the Beira Private Hospital transaction from internally generated cash. In support of the Group's growth aspirations, we continue to retain sufficient funding headroom in respect of banking facilities. On 31 August 2023, the Group's gearing level (Net Debt to EBITDA for the last 12 months) was at 2.0 times compared to 1.7 times at the end of the prior period.

Cash generated from operating activities as a percentage of EBITDA was in line with the prior year at 82%. This is lower than our target of 90% of EBITDA, largely due to the significant growth in revenues and the resultant increase in the receivables book. Despite the increase in the receivables book, the trade receivables days outstanding remained within our target range. We anticipate collection trends to remain in line with previous periods.

In keeping with our commitment to shareholders, the Group paid a dividend of 4.22 c per share during July 2023, a 21% increase from the prior period. This dividend is in line with our dividend policy of paying at least 10% of headline earnings attributable to shareholders annually.

## Segmental analysis

### South African operations (refer Note 1 below)

Revenue for the South African operations improved by 30% to R1 762.1 million compared to R1 353.7 million in the same period last year. If we had to exclude MMHS from both the current and prior year, the increase would have been 17%. MMHS was included in the results this year for the full six months while only included for one month of the prior period. This growth in revenue is attributable to an increase in Paid Patient Days (PPDs) of 25% (10%), and an increase in the Rand per Patient Day (RPPD) of 4% (7%) with the length of stay marginally reducing to 4 days. The lower growth in RPPD of 4% was anticipated, as MMHS has a lower RPPD compared to the rest of the South African operations. This is due to the higher proportion of day and mental health cases in relation to the rest of the Group. The expansions at EHHC and RHHC pertaining

Note 1 – As a result of the MMHS acquisition with effect from 1 August 2022, the number in brackets indicates the results of the South African operations exclusive of MMHS's performance.



## Group Performance review *continued*

to additional higher acuity beds, have positively contributed to growth. Our facilities in the KZN coastal region contributed positively to the revenue growth on the mentioned bed expansion as well as increased utilisation following the floods in KZN during April 2022.

EBITDA for the South African operations increased by 23% (14%) to R300.7 million (R273.2 million) from R244.6 million (R240.3 million) in 2022 at a constant margin of 18% (18.8%). This result is indicative of increased cost of doing business in South Africa, with municipal charges and additional cost resulting from load shedding increasing 38% year-on-year. In an attempt to reduce the impact of future expected price increases in energy and municipal costs, the Group is driving the roll out of green initiatives to reduce electricity and water consumption. The operating leverage in the South African operations caused growth in core EBITDA to exceed growth in revenue over the period.

At a significantly lower EBITDA margin compared to the Group average, we recognise the opportunity in aligning MMHS's margin to the Group average over the next 24 months. Various initiatives are underway in this regard that should contribute positively to the margins in the future.

### **Operations outside of South Africa**

Revenue for the operations outside of South Africa improved by 21% to R620.8 million compared to R514.4 million in the same period last year. The increase would have been 9.7% at constant exchange rates.

This revenue improvement is attributable to an increase in Paid Patient Days (PPDs) of 4%, and an increase in the Rand per Patient Day (RPPD) of 16% (6%), with the length of stay marginally increasing.

EBITDA for the foreign operations declined by 6% to R79.3 million compared to R84.6 million. The activity at our Maputo Laboratory reduced by 37%, as a direct result of the business normalising post Covid-19. In addition, Beira Private Hospital was a loss-making operation at acquisition date and

hence not contributing to EBITDA during the current period. Early indications are that the Beira operations are approaching break-even, and we are confident that it will positively contribute to profitability in the near term.

During the period under review, a new academic hospital was opened by the Ministry of Health of Botswana, resulting in lower activity levels at Bokamoso Private Hospital (Bokamoso) compared to our initial expectations. This, together with changes to the VAT regulations and increased rental on the extension of the lease for Bokamoso resulted in a decline in EBITDA for the period. This trend is expected to continue into the second half of the year. We remain agile to the opportunities and challenges in this market and are actively driving the repositioning of this business.

## Prospects

We remain cautiously optimistic for the remainder of the financial year. Growth is expected to taper off in the second half of the year, as a result of the competitive dynamics experienced in our Botswana facility.

The South African operating platform continues to deliver strong performance with identified pockets for attractive growth. Projects are at various stages of execution, and we are hopeful that these will contribute positively to case mix, revenue and profitability over the short to medium term.

The subdued economic growth and poor macroeconomic outlook of the South African and other African economies presents many challenges; however, Lenmed is well-versed in identifying attractive opportunities under these conditions and remains ideally positioned to take advantage of well-considered growth initiatives. We strive to execute on our growth and value unlock strategy, in a responsible and sustainable manner, actively seeking to increase our market share, acquire attractive businesses and diversify our revenue base, while ensuring that we continue to strengthen our core. We thank all of our stakeholders for their support and commitment to the Group.

## Condensed Statement of Comprehensive Income

	<b>GROUP</b>		
Figures in R'000	Unaudited six months ended 31 August 2023	Unaudited six months ended 31 August 2022	Audited year ended 28 February 2023
<b>Profit and Loss</b>			
Revenue	<b>2 382 865</b>	1 868 045	3 972 201
Cost of sales	<b>(736 134)</b>	(580 136)	(1 224 669)
<b>GROSS PROFIT</b>	<b>1 646 731</b>	1 287 909	2 747 532
Other income	<b>93 640</b>	66 574	150 737
Operating costs	<b>(1 445 984)</b>	(1 109 234)	(2 424 790)
<b>PROFIT BEFORE INTEREST AND TAXATION</b>	<b>294 387</b>	245 249	473 479
Share of profit from associates	<b>290</b>	1 681	2 669
Investment income	<b>4 010</b>	4 154	11 136
Finance costs	<b>(90 505)</b>	(59 089)	(141 328)
<b>PROFIT BEFORE TAXATION</b>	<b>208 182</b>	191 995	345 956
Taxation	<b>(50 832)</b>	(46 685)	(85 363)
<b>PROFIT FOR THE PERIOD</b>	<b>157 350</b>	145 310	260 593
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified subsequently to profit and loss</i>			
Foreign currency translation reserve	<b>45 024</b>	17 679	104 036
Cash flow hedging reserve for interest rate hedging instrument	<b>-</b>	3 139	3 139
<b>Total other comprehensive income for the period</b>	<b>45 024</b>	20 818	107 175
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>202 374</b>	166 128	367 768
<b>Profit for the period attributable to:</b>			
Non-controlling interests	<b>21 191</b>	13 528	48 296
Lenmed Investments Limited equity holders	<b>136 159</b>	131 782	212 297
	<b>157 350</b>	145 310	260 593
<b>Total comprehensive income for the period attributable to:</b>			
Non-controlling interests	<b>23 808</b>	17 069	49 662
Lenmed Investments Limited equity holders	<b>178 566</b>	149 059	318 106
	<b>202 374</b>	166 128	367 768
Earnings per share (cents)	<b>19.19</b>	18.57	29.92

## Headline Earnings

Figures in R'000	GROUP		
	Unaudited six months ended 31 August 2023	Unaudited six months ended 31 August 2022	Audited year ended 28 February 2023
Profit for the period attributable to Lenmed	<b>136 159</b>	131 782	212 297
Add/Less: (Profit)/loss on disposal of assets	<b>(205)</b>	-	497
Add/Less: Currencies (gains) and losses	<b>(85)</b>	628	-
	<b>135 869</b>	132 410	212 794
<b>HEADLINE EARNINGS PER SHARE (CENTS)</b>	<b>19.15</b>	18.66	29.99

## Normalised EBITDA

Figures in R'000	GROUP		
	Unaudited six months ended 31 August 2023	Unaudited six months ended 31 August 2022	Audited year ended 28 February 2023
<b>EBITDA</b>	<b>379 952</b>	329 163	635 001
(Profit)/loss on disposal of assets	<b>(280)</b>	-	-
Currencies (gains) and losses	<b>(117)</b>	873	-
	<b>379 555</b>	330 036	635 001

## Condensed Statement of Financial Position

		<b>GROUP</b>		
Figures in R'000	Notes	Unaudited six months ended 31 August 2023	Unaudited six months ended 31 August 2022	Audited year ended 28 February 2023
<b>Assets</b>				
<b>NON-CURRENT ASSETS</b>				
Property, plant and equipment and investment property		<b>3 400 691</b>	3 068 656	3 185 853
Right-of-use assets		<b>178 752</b>	174 201	180 960
Goodwill	3	<b>559 056</b>	549 373	546 895
Intangible assets		<b>51 131</b>	39 917	37 675
Investment in associates		<b>12 864</b>	11 254	12 573
Deferred tax		<b>70 160</b>	64 473	73 272
		<b>4 272 654</b>	3 907 874	4 037 228
<b>CURRENT ASSETS</b>				
Inventory		<b>113 002</b>	97 519	98 643
Trade and other receivables		<b>1 216 396</b>	1 023 874	1 065 377
Taxation assets		-	15 121	-
Cash and cash equivalents		<b>307 692</b>	505 460	310 512
		<b>1 637 090</b>	1 641 974	1 474 532
<b>TOTAL ASSETS</b>		<b>5 909 744</b>	5 549 848	5 511 760
<b>Equity and Liabilities</b>				
<b>Equity and Reserves</b>				
Stated capital		<b>426 006</b>	426 006	426 006
Other Reserves		<b>309 258</b>	178 319	266 851
Accumulated profits		<b>1 890 538</b>	1 703 806	1 784 320
Non-controlling interests		<b>362 107</b>	281 073	309 298
		<b>2 987 909</b>	2 589 204	2 786 475
<b>NON-CURRENT LIABILITIES</b>				
Long term liabilities		<b>1 401 936</b>	1 122 027	1 470 599
Loans from non-controlling interests		<b>25 959</b>	29 395	23 206
Lease liabilities		<b>210 486</b>	193 052	212 849
Deferred taxation		<b>242 018</b>	238 348	237 145
		<b>1 880 399</b>	1 582 822	1 943 799
<b>CURRENT LIABILITIES</b>				
Trade and other payables		<b>742 005</b>	1 177 422	635 179
Current portion of long term liabilities		<b>136 000</b>	98 000	103 288
Current portion of loans from non-controlling interests		-	-	6 925
Current portion of lease liabilities		<b>17 766</b>	16 070	12 599
Taxation liabilities		<b>41 527</b>	24 665	2 015
Bank overdraft		<b>104 138</b>	61 665	21 480
		<b>1 041 436</b>	1 377 822	781 486
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>5 909 744</b>	5 549 848	5 511 760

# Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

## Condensed Statements of Changes in Equity

### GROUP

Figures in R'000	Stated capital	Foreign currency translation reserve	Accumulated profits	Equity attributable to Group	Non-controlling interest	Total
<b>BALANCE AT 31 AUGUST 2022</b>	426 006	178 319	1 703 806	2 308 131	281 073	<b>2 589 204</b>
Profit for the period	-	-	105 348	105 348	34 767	<b>140 115</b>
Other comprehensive income	-	88 532	-	88 532	(2 175)	<b>86 357</b>
Dividends	-	-	(24 834)	(24 834)	(4 367)	<b>(29 201)</b>
<b>BALANCE AT 28 FEBRUARY 2023</b>	426 006	266 851	1 784 320	2 477 177	309 298	<b>2 786 475</b>
Profit for the period	-	-	136 159	136 159	21 191	<b>157 350</b>
Other comprehensive income	-	42 407	-	42 407	2 617	<b>45 024</b>
Acquisition of subsidiary	-	-	-	-	33 185	<b>33 185</b>
Dividends	-	-	(29 941)	(29 941)	(4 184)	<b>(34 125)</b>
<b>BALANCE AT 31 AUGUST 2023</b>	426 006	309 258	1 890 538	2 625 802	362 107	<b>2 987 909</b>



## Condensed Statement of Cash Flows

		<b>GROUP</b>		
Figures in R'000	Notes	Unaudited six months ended 31 August 2023	Unaudited six months ended 31 August 2022	Audited year ended 28 February 2023
<b>Cash flows from operating activities</b>				
<b>OPERATING CASH FLOW BEFORE WORKING CAPITAL CHANGES</b>		<b>379 952</b>	306 920	635 691
<i>Working capital changes</i>				
Decrease in trade and other receivables		<b>(168 894)</b>	(58 792)	(148 305)
Increase in inventory		<b>(15 254)</b>	(3 524)	(3 448)
Increase/(decrease) in trade and other payables		<b>116 470</b>	(78 452)	51 654
<b>CASH GENERATED BY OPERATING ACTIVITIES</b>		<b>312 274</b>	166 152	535 592
Investment income		<b>4 010</b>	4 154	11 136
Finance costs		<b>(90 505)</b>	(52 556)	(139 431)
Income tax paid		<b>(28 705)</b>	(18 554)	(64 989)
<b>NET CASH FROM OPERATING ACTIVITIES</b>		<b>197 074</b>	99 196	342 308
<b>Cash flows from investing activities</b>				
Property, plant and equipment acquired		<b>(145 143)</b>	(63 000)	(161 283)
Proceeds on disposal of Property, plant and equipment		-	-	10 326
Intangible assets acquired		-	(4 515)	(17 419)
Investment in subsidiary		<b>(59 460)</b>	-	(419 438)
	3			
<b>NET CASH UTILISED IN INVESTING ACTIVITIES</b>		<b>(204 603)</b>	(67 515)	(587 814)
<b>Cash flows from financing activities</b>				
Net loans (repaid)/raised		<b>(40 123)</b>	95 852	391 754
Lease liability paid		<b>(5 608)</b>	(6 146)	(8 264)
Dividends paid		<b>(34 244)</b>	(24 833)	(29 136)
<b>NET CASH GENERATED BY FINANCING ACTIVITIES</b>		<b>(79 975)</b>	64 873	354 354
(Decrease)/Increase in cash and cash equivalents		<b>(87 504)</b>	96 554	108 848
Effect of exchange rate changes on cash and cash equivalents		<b>2 026</b>	8 728	18 065
Cash acquired on acquisition		-	176 394	-
Cash and cash equivalents at beginning of the period/year		<b>289 032</b>	162 119	162 119
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD/YEAR</b>		<b>203 554</b>	443 795	289 032

## Accounting policies

### 1. Basis of preparation

These condensed unaudited consolidated interim financial statements for the six months ended 31 August 2023 have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), IAS 34 Interim Financial Reporting Standard, comply with SAICA Financial Reporting Guides as issued by the Accounting Practices Committee, Financial Reporting Announcements issued by the Financial Reporting Standards Council and the Companies Act of South Africa. These policies have been consistently applied to all periods presented, unless otherwise stated. They have been prepared on the historical cost basis, unless otherwise stated. This report was compiled under the supervision of Fredre Meiring CA (SA). The Board takes full responsibility for the preparation of these financial results. The accounting policies used in the preparation of these results are in accordance with IFRS and consistent in all material respect with those of the previous annual financial statements.

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that may affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods. The interim results have not been reviewed or audited by the Group's external independent auditors, PKF Durban.

---

### 2. Condensed Segment Information

Consistent with the Group's internal reporting, the chief operating decision maker, being the EXCO, views the Group's operating results as a single segment and makes the decisions about resources to be allocated and assesses performance accordingly.

The IFRS 8 required information about the group as a single segment for profit or loss, including specified revenues and expenses, and assets and liabilities have already been discussed elsewhere in these interim results.

---

## Notes to interim financial statements

### 3. Business combination

#### 3.1 Details of acquisition

The Group acquired 60% in Beira Private Hospital Limitada in the town of Beira in Mozambique effective 15 March 2023 for R59.460 million. The hospital comprises a 60 bed facility and an outpatient clinic. The acquisition of this stake aligns with our strategy of expanding our group's footprint in Mozambique. With this acquisition, we are confident that we can enhance our presence in the healthcare sector in Mozambique and provide quality healthcare services.

#### 3.2 Assets acquired and liabilities recognised at the date of acquisition

Recognised amounts of identifiable assets acquired and liabilities of Beira Private Hospital

Figures in R'000	Unaudited six months ended 31 August 2023
<b>NON-CURRENT ASSETS</b>	
Property, plant and equipment	82 962
Goodwill arising on acquisition	9 683
Less non-controlling interest	(33 185)
<b>CONSIDERATION TRANSFERRED</b>	<b>59 460</b>

The goodwill of R9.7 million is attributable to the potential high profitability of the acquired business. It will not be deductible for tax purposes.

#### 3.3 Impact of acquisitions on the results of the Group

Revenue since acquisition included in results	3 729
Profit since acquisition included in results	(1 916)

### 4. Revenue

An analysis of revenue is as follows:

Tariff	1 691 404
Non-tariff	691 461
<b>Total revenue</b>	<b>2 382 865</b>

There were no outstanding performance obligations at year end.

### 5. Events after the reporting date

On 1 October 2023, Lenmed Health acquired 100% of the ordinary shares of Mooimed Operating Company (Pty) (Mooimed) Ltd for the sum of R146 million, a private hospital company based in Potchefstroom. This amount is subject to change depending on the final audited cash and working capital balances of Mooimed. The objective of the acquisition is to expand our footprint in the North-West province of South Africa.

The agreed price will be settled in two tranches. The first tranche of R106 million was settled on 30 September 2023. The second tranche of provisionally R40 million, depending on the final audited results, will be settled no later than 60 days from 1 October 2023.

# Company information

## Country of incorporation

South Africa

## Nature of business

The provision of private patient healthcare, through management and ownership of hospitals and other related health services.

## Executive directors

- Mr Prakash Devchand
- Mr Amil Devchand
- Mr Fredré Meiring

## Non-executive Directors

- Mr Mike Meehan (*lead independent*)
- Ms Bharti Harie (*independent*)
- Ms Nomahlubi Simamane (*independent*)
- Mr Vaughan Firman (*independent*)
- Prof Bhaskar Goolab
- Dr Gunvant Goolab (*independent*)

## Registered address

2nd Floor Fountain View House,  
Constantia Office Park,  
Corner 14th Avenue and  
Hendrik Potgieter Road, Constantia Kloof,  
**Johannesburg**, 1709

## Postal address

PO Box 855, Lenasia,  
**Johannesburg**, 1820

## Auditors

PKF Durban, Chartered Accountants (SA)

## Registered Auditors

Practice number - 906352E  
2nd Floor, 12 on Palm Boulevard  
Gateway, **KwaZulu-Natal**, 4319

## Company secretary

Mr W Somerville  
Bryanston Gate, Block 4, 1st Floor,  
Homestead Avenue, Bryanston,  
**Johannesburg**, 2191

## Registration number

1980/003108/06

## Bankers

Rand Merchant Bank

## Transfer secretary

Singular Systems (Pty) Ltd t/a  
Equity Express, 25 Scott Street,  
Waverley, **Johannesburg**, 2090

## Our hospitals

### Ahmed Kathrada Private Hospital

K43 Highway, Extension 8, Lenasia,  
**Gauteng**

T +27 87 087 0642 • F +27 11 852 8910

### Beira Private Hospital

Estrada Carlos Pereira, Estoril,  
**Beira**

T +258 8614 44453

### Bokamoso Private Hospital

Plot 2435, Block 1, Mmopane,  
Along the Molepolole Road, Gaborone,  
**Botswana**

T +267 369 4000 • F +267 369 4140

### Daleside Day Hospital

12 Van Ryneveld Street, Wilkoppies,  
**Klerksdorp**

T +27(0) 18 464 1009

### Daxina Private Hospital

1682 Impala Street, Lenasia South,  
**Gauteng**

T +27 87 087 0644 • F +27 11 855 1039

### Ethekwini Hospital and Heart Centre

11 Riverhorse Drive, Riverhorse Valley  
Business Estate, Queen Nandi Drive,  
Durban,  
**KwaZulu-Natal**

T +27 31 581 2400 • F +27 31 581 2999

### Howick Private Hospital

107 Main Street,  
**Howick**, 3290

T +27 33 330 2456

### Kathu Private Hospital

Frikkie Meyer Street,  
**Kathu**

T +27 87 158 2700

### La Verna Private Hospital

1 Convent Road, Ladysmith,  
**KwaZulu-Natal**

T +27 87 087 2600

### Maputo Private Hospital

Rua do Rio Inhamiara,  
Sommerschield II, Maputo,  
**Mozambique**

T +258 84 303 0967-9 • F +258 21 49 3680

### Mooimed Private Hospital

1 Chief Albert Luthuli Drive,  
**Potchefstroom**, 2531

T +27 (0) 18 293 0802

### Parkmed Neuro Clinic

94 Bishop Desmond Tutu St, Naserhof,  
**Klerksdorp**, 2571

T +27 (0) 18 462 3072

### Randfontein Private Hospital

Lister Road, Lower Ward Street Extension,  
**Randfontein**

T +27 87 087 2700

### Royal Hospital and Heart Centre

Corner Welgevonden and  
Jacobus Smit Street, Royldene,  
**Kimberley**

T +27 53 045 0350

### Shifa Private Hospital

482 Randles Road, Sydenham, Durban,  
**KwaZulu-Natal**

T +27 87 087 0641

### Sunningdale Private Hospital

12 Van Ryneveld Street, Wilkoppies,  
**Klerksdorp**

T +27(0)18 462 7536

### The Bank Hospital

Block F6, Shippi Road,  
Cantonments,  
**Accra**

T +233 302 739 373

### Wilmed Park Private Hospital

Cnr Ametis & Marmer Street,  
**Wilkoppies**, 2571

T +27 (0)18 468 7700

### Zamokuhle Private Hospital

128 Flint Mazibuko Street,  
Hospital View, Tembisa,  
**Gauteng**

T +27 87 087 0643

